Latest Conference Articles

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

A brief introduction to the topics and focus of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Jeffrey Crawford, MD, from Duke University Medical Center, on Managing Febrile Neutropenia.

A compilation of photos from the 2012 combined conferences of the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO).

Dr. Jimmie Holland, from Memorial Sloan-Kettering Cancer Center, on the Stigma Toward Psychosocial Care.

Recent evidence shows that some of the newer molecularly targeted therapies can cause diarrhea, which can lead to dose reductions and alterations.

Although molecularly targeted agents can cause cardiac damage, it appears to be reversible and related to cellular dysfunction, as distinct from agents such as anthracyclines that cause cellular death and irreversible cardiac dysfunction.

Dr. Richard Gralla, from the Quality of Life Research Associates, on Chemotherapy-Induced Nausea and Vomiting.

Dr. Kathleen Foley, from Memorial Sloan-Kettering Cancer Center, Discusses the World Health Organization Guidelines for Cancer Pain Management.

Dr. Steven Grunberg, from the Vermont Cancer Center, Describes the 2012 Multinational Association of Supportive Care in Cancer Symposium.

Control of chemotherapy-induced nausea and vomiting (CINV) has come a long way in the past 30 years. Thirty years ago, about 10% of patients had complete control of emesis; in the 1990s about 50% had complete control. Today about 85% of patients treated with highly emetogenic chemotherapy have complete control of emesis.

Treatment of febrile neutropenia (FN) has dramatically improved over the past 3 decades, but there is room for improvement, according to Jean Klastersky, MD, Institut Jules Bordet, Brussels, Belgium.

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.